- Open
- 4.45
- High
- 4.49
- Low
- 3.80
- Close
- 3.90
- Change
- -0.50 (-11.36%)
- Volume
- 17,044,741
| 30 Jul 2026 | 07:00:04 | Q2 and H1 2026 Trading Update |
| 28 Jul 2026 | 07:00:06 | ACCRUFeR® Phase 3 pediatric trial published |
| 30 Jun 2026 | 07:52:15 | Block Listing 6 Monthly Return |
| 18 Jun 2026 | 16:20:59 | Results of 2026 Annual General Meeting |
| 29 May 2026 | 09:11:15 | Total Voting Rights |
| 25 Jun 2026 | Shield Therapeutics plc 2025 Annual Report and Accounts | |
| 29 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 6 Jun 2025 | Annual Report and Accounts (to 2024-12-31) |
Shield Therapeutics PLC is a specialty pharmaceutical company focused on addressing iron deficiency. It develops and commercializes ACCRUFeR®, a non-salt based oral treatment for adults with iron deficiency, regardless of anaemia status. The company operates through partnerships, primarily with Viatris, to drive prescription demand and optimize distribution channels in the U.S. Shield is also expanding its product indications to include children and supports global licensing partners in various markets, including Japan, South Korea, China, Canada, and Europe.
| 30 Jul 2026 | 07:00:04 | Q2 and H1 2026 Trading Update |
| 28 Jul 2026 | 07:00:06 | ACCRUFeR® Phase 3 pediatric trial published |
| 30 Jun 2026 | 07:52:15 | Block Listing 6 Monthly Return |
| 18 Jun 2026 | 16:20:59 | Results of 2026 Annual General Meeting |
| 29 May 2026 | 09:11:15 | Total Voting Rights |
| 25 Jun 2026 | Shield Therapeutics plc 2025 Annual Report and Accounts | |
| 29 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 6 Jun 2025 | Annual Report and Accounts (to 2024-12-31) |
Shield Therapeutics PLC is a specialty pharmaceutical company focused on addressing iron deficiency. It develops and commercializes ACCRUFeR®, a non-salt based oral treatment for adults with iron deficiency, regardless of anaemia status. The company operates through partnerships, primarily with Viatris, to drive prescription demand and optimize distribution channels in the U.S. Shield is also expanding its product indications to include children and supports global licensing partners in various markets, including Japan, South Korea, China, Canada, and Europe.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £253m | -0.1% | |
| £124m | +0.0% | |
| £108m | -0.0% | |
| £84m | +0.2% | |
STXShield Therapeutics PLC | £42m | -0.0% |
| £11m | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £253m | -0.1% | |
| £124m | +0.0% | |
| £108m | -0.0% | |
| £84m | +0.2% | |
STXShield Therapeutics PLC | £42m | -0.0% |
| £11m | -0.2% |